Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases.
Adaptive radiotherapy
Intra-fraction variability
Lymph node
MR-linac
MRgRT
Oligometastases
SBRT
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
11
05
2021
accepted:
30
06
2021
pubmed:
17
7
2021
medline:
25
2
2023
entrez:
16
7
2021
Statut:
ppublish
Résumé
We report preliminary dosimetric data concerning the use of 1.5-T MR-guided daily-adaptive radiotherapy for abdomino-pelvic lymph-nodal oligometastases. We aimed to assess the impact of this technology on mitigating daily variations for both target coverage and organs-at-risk (OARs) sparing. A total of 150 sessions for 30 oligometastases in 23 patients were analyzed. All patients were treated with MR-guided stereotactic body radiotherapy (SBRT) for a total dose of 35 Gy in five fractions. For each fraction, a quantitative analysis was performed for PTV volume, V35Gy and D Average baseline PTV, bowel, bladder, and single intestinal loop volumes were respectively 8.9 cc (range 0.7-41.2 cc), 1176 cc (119-3654 cc), 95 cc (39.7-202.9 cc), 18.3 cc (9.1-37.7 cc). No significant volume variations were detected for PTV (p = 0.21) bowel (p = 0.36), bladder (p = 0.47), except for single intestinal loops, which resulted smaller (p = 0.026). Average baseline V35Gy and D Daily-adaptive MR-guided SBRT reported a significantly improved single intestinal loop sparing for lymph-nodal oligometastases. Also, bowel D
Identifiants
pubmed: 34268583
doi: 10.1007/s00432-021-03739-8
pii: 10.1007/s00432-021-03739-8
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3269-3277Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L et al (2020) 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol 15(1):69. https://doi.org/10.1186/s13014-020-01510-w
doi: 10.1186/s13014-020-01510-w
pubmed: 32248826
pmcid: 7092497
Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, Ricchetti F, Vitale C, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Mazzola R (2021) Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. Br J Radiol 94(1117):20200848. https://doi.org/10.1259/bjr.20200848
doi: 10.1259/bjr.20200848
pubmed: 33095659
Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37:4078–4101
doi: 10.1118/1.3438081
Corradini S, Alongi F, Andratschke N, Belka C, Boldrini L, Cellini F et al (2019) MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol 14:92. https://doi.org/10.1186/s13014-019-1308-y
doi: 10.1186/s13014-019-1308-y
pubmed: 31167658
pmcid: 6551911
Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J et al (2020) Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clin Transl Radiat Oncol 29(23):35–42. https://doi.org/10.1016/j.ctro.2020.04.011
doi: 10.1016/j.ctro.2020.04.011
Henke L, Kashani R, Yang D, Zhao T, Green O, Olsen L et al (2016) Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: characterization of potential advantages. Int J Radiat Oncol Biol Phys 96:1078–1086. https://doi.org/10.1016/j.ijrobp.2016.08.036
doi: 10.1016/j.ijrobp.2016.08.036
pubmed: 27742541
pmcid: 5376349
Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J et al (2018) Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 126:519–526. https://doi.org/10.1016/j.radonc.2017.11.032]
doi: 10.1016/j.radonc.2017.11.032]
pubmed: 29277446
Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A et al (2012) Robotic imageguided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897. https://doi.org/10.1016/j.ijrobp.2010.11.031
doi: 10.1016/j.ijrobp.2010.11.031
pubmed: 21277113
Kurup G (2010) CyberKnife: a new paradigm in radiotherapy. J Med Phys 35:63–64. https://doi.org/10.4103/0971-6203.62194
doi: 10.4103/0971-6203.62194
pubmed: 20589114
pmcid: 2884306
Lehrer EJ, Singh R, Wang M et al (2020) Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.6146 (published online November 25)
doi: 10.1001/jamaoncol.2020.6146
Mazzola R, Jereczek-Fossa BA, Franceschini D et al (2020a) Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiat Oncol 15(1):92. https://doi.org/10.1186/s13014-020-01544-0 (published 2020 May 4)
doi: 10.1186/s13014-020-01544-0
pubmed: 32366258
pmcid: 7197157
Mazzola R, Figlia V, Rigo M, Cuccia F, Ricchetti F, Giaj-Levra N et al (2020b) Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. J Cancer Res Clin Oncol 146(9):2379–2397. https://doi.org/10.1007/s00432-020-03230-w
doi: 10.1007/s00432-020-03230-w
pubmed: 32372146
Ng SSW, Ning MS, Lee P, McMahon RA, Siva S, Chuong MD (2020) Single-fraction stereotactic body radiation therapy: a paradigm during the coronavirus disease 2019 (COVID-19) pandemic and beyond? Adv Radiat Oncol 5(4):761–773. https://doi.org/10.1016/j.adro.2020.06.011 (published 2020 Jun 24)
doi: 10.1016/j.adro.2020.06.011
pubmed: 32775790
pmcid: 7406732
Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, De Simone A, Giaj-Levra N, Mazzola R, Naccarato S, Ricchetti F, Vitale C, Ruggieri R, Alongi F (2021) Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol 60(2):215–221. https://doi.org/10.1080/0284186X.2020.1821090
doi: 10.1080/0284186X.2020.1821090
pubmed: 32945701
Noel CE, Parikh PJ, Spencer CR, Green OL, Hu Y, Mutic S et al (2015) Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy. Acta Oncol 54:1474–1482. https://doi.org/10.3109/0284186X.2015.1062541
doi: 10.3109/0284186X.2015.1062541
pubmed: 26206517
Onderdonk BE, Gutiontov SI, Chmura SJ (2020) The evolution (and future) of stereotactic body radiotherapy in the treatment of oligometastatic disease. Hematol Oncol Clin North Am 34(1):307–320. https://doi.org/10.1016/j.hoc.2019.09.003
doi: 10.1016/j.hoc.2019.09.003
pubmed: 31739951
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Osti MF, Agolli L, Valeriani M, Reverberi C, Bracci S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L (2018) 30 Gy single dose stereotactic body radiation therapy (SBRT): report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer 122:165–170. https://doi.org/10.1016/j.lungcan.2018.06.018
doi: 10.1016/j.lungcan.2018.06.018
pubmed: 30032826
Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Poon I, Erler D, Dagan R et al (2020) Evaluation of definitive stereotactic body radiotherapy and outcomes in adults with extracranial oligometastasis. JAMA Netw Open 3(11):e2026312. https://doi.org/10.1001/jamanetworkopen.2020.26312
doi: 10.1001/jamanetworkopen.2020.26312
pubmed: 33196810
pmcid: 7670310
Raaymakers BW, Jurgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte A, van Asselen B et al (2017) First patients treated with a 1.5 T MRI-linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 62:L41–L50. https://doi.org/10.1088/1361-6560/aa9517
doi: 10.1088/1361-6560/aa9517
pubmed: 29135471
Ruggieri R, Rigo M, Naccarato S, Gurrera D, Figlia V, Mazzola R, Ricchetti F, Nicosia L, Giaj-Levra N, Cuccia F, Vitale C, Stavreva N, Pressyanov DS, Stavrev P, Pellegrini R, Alongi F (2020) Adaptive SBRT by 1.5 T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time. Phys Med 80:34–41. https://doi.org/10.1016/j.ejmp.2020.09.026
doi: 10.1016/j.ejmp.2020.09.026
pubmed: 33091796
Schippers MG, Bol GH, de Leeuw AA et al (2014) Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer. Radiother Oncol 111(3):442–445. https://doi.org/10.1016/j.radonc.2014.05.013
doi: 10.1016/j.radonc.2014.05.013
pubmed: 25034933
Shahi J, Poon I, Ung YC et al (2020) Stereotactic body radiation therapy for mediastinal and hilar lymph node metastases. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2020.10.004 (published online ahead of print, 2020 Oct 25)
doi: 10.1016/j.ijrobp.2020.10.004
pubmed: 33115687
Sogono P, Bressel M, David S et al (2020) Safety, efficacy, and patterns of failure after single-fraction stereotactic body radiation therapy (SBRT) for oligometastases. Int J Radiat Oncol Biol Phys 109(3):756–763. https://doi.org/10.1016/j.ijrobp.2020.10.011 (published online ahead of print, 2020 Oct 15)
doi: 10.1016/j.ijrobp.2020.10.011
pubmed: 33069796
pmcid: 7560377
Van Wickle JD, Paulson ES, Landry JC, Erickson BA, Hall WA (2017) Adaptive radiation dose escalation in rectal adenocarcinoma: a review. J Gastrointest Oncol 8:902–914. https://doi.org/10.21037/jgo.2017.07.06
doi: 10.21037/jgo.2017.07.06
pubmed: 29184696
pmcid: 5674246
Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH et al (2019) Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: multi-fraction treatment of pelvic lymph node oligometastases. Radiother Oncol 134:50–54. https://doi.org/10.1016/j.radonc.2019.01.024
doi: 10.1016/j.radonc.2019.01.024
pubmed: 31005224
Winkel D, Kroon PS, Werensteijn-Honingh AM, Bol GH, Raaymakers BW, Jürgenliemk-Schulz IM (2018) Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5 T MR-linac. Acta Oncol. https://doi.org/10.1080/0284186X.2018.1512152
doi: 10.1080/0284186X.2018.1512152
pubmed: 30280631
Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM et al (2019a) Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol. https://doi.org/10.1016/j.ctro.2019.04.001
doi: 10.1016/j.ctro.2019.04.001
pubmed: 31341976
pmcid: 6630157
Winkel D, Bol GH, Werensteijn-Honingh AM et al (2019b) Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance. Phys Imaging Radiat Oncol 9:58–64. https://doi.org/10.1016/j.phro.2019.02.003 (published 2019 Mar 1)
doi: 10.1016/j.phro.2019.02.003
pubmed: 33458426
pmcid: 7807584
Winkel D, Bol GH, Werensteijn-Honingh AM, Intven MPW, Eppinga WSC, Hes J et al (2020) Target coverage and dose criteria based evaluation of the first clinical 1.5 T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment. Radiother Oncol 146:118–125. https://doi.org/10.1016/j.radonc.2020.02.011
doi: 10.1016/j.radonc.2020.02.011
pubmed: 32146257
Wong A, Pitroda S, Watson S, Son C, Das LC, Uppal A, Oshima G, Stack M, Khodarev N, Salama J, Posner M, Weichselbaum R, Chmura S (2015) Long-term survivors of an SBRT dose-escalation study for oligometastases: clinical and molecular markers. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2015.07.152
doi: 10.1016/j.ijrobp.2015.07.152
pubmed: 27026318
pmcid: 4814325